Side-by-side comparison of AI visibility scores, market position, and capabilities
Open-source observability leader with $6B valuation; Grafana dashboards plus Loki/Tempo/Mimir stack serving millions of installations as Datadog alternative with community-driven adoption.
Grafana Labs is the company behind Grafana — the world's most widely used open-source observability and data visualization platform — providing the Grafana Cloud managed service, Grafana Enterprise, and a suite of open-source tools including Loki (log aggregation), Tempo (distributed tracing), and Mimir (long-term Prometheus metrics storage). Founded in 2019 by Raj Dutt, Torkel Ödegaard, and Tom Wilkie (the creators of the original Grafana open-source project) in New York, Grafana Labs has raised over $600 million at a $6 billion valuation.\n\nGrafana's open-source project — downloadable and self-hostable for free — has driven extraordinary community adoption: millions of Grafana installations globally power engineering, IoT, and business dashboards at organizations from startups to large enterprises. Grafana's plugin ecosystem connects to 200+ data sources (Prometheus, InfluxDB, Elasticsearch, AWS CloudWatch, databases), making it the universal observability visualization layer. Grafana Cloud packages the open-source tools into a fully managed SaaS offering with unlimited metrics, logs, traces, and dashboards.\n\nIn 2025, Grafana Labs competes in the observability platform market against Datadog, New Relic, Dynatrace, and the ELK/OpenSearch stack for enterprise monitoring and observability. Grafana's open-source-first model creates a moat through developer community and ecosystem — engineers who build personal dashboards on Grafana become advocates for Grafana Cloud at their employers. The company's OpenTelemetry alignment and multi-source data philosophy ("query any data, anywhere") differentiates it from Datadog's monolithic agent model. The 2025 strategy focuses on growing Grafana Cloud enterprise adoption, advancing AI-powered Sift (automatic anomaly investigation), and expanding the Grafana IRM (incident response management) product.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.